Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
核心洞察
Michael S. Perry, a Director at Arrowhead Pharmaceuticals, sold 11,600 shares of common stock on Aug. 18, 2026, according to an SEC Form 4 filing.
The transaction was valued at approximately $1 million, with shares disposed of at prices ranging from $87.20 to $87.44.
The sale liquidated 9% of Perry's direct holdings, leaving him with 111,459 directly held shares and 0.0791% of the company's equity.
Michael S. Perry, a Director at Arrowhead Pharmaceuticals (NASDAQ: ARWR), sold 11,600 shares of common stock on Aug. 18, 2026, according to an SEC Form 4 filing. The transaction, valued at approximately $1 million, was executed in multiple open-market transactions at prices ranging from $87.20 to $87.44, with a weighted average sale price of $87.30.
Transaction Details and Insider Stake
The shares were disposed of in multiple transactions, with the reporting person providing full trade data to the company and the SEC upon request. By selling 11,600 shares, the director liquidated 9% of his direct holdings. However, he remains a stakeholder with 0.0791% of the company's equity and continues to hold common stock underlying unvested restricted stock units.
Following the transaction, Perry directly holds 111,459 shares, with a post-transaction value of $9.8 million based on the Aug. 18, 2026, market close of $87.90.
Company Valuation and Financial Position
The Pasadena-based biotechnology company maintains a market capitalization of $12.2 billion, with shares priced at $89.41 as of the Aug. 19, 2026, market close. Arrowhead Pharmaceuticals reported trailing twelve-month revenue of $669.5 million and a net loss of $320 million as it continues to advance a therapeutic pipeline centered on RNA interference (RNAi) technology.
Founded in 1989 and headquartered in Pasadena, California, Arrowhead operates as a discovery-stage to clinical-stage biopharmaceutical enterprise with 711 employees. The company targets patients with rare genetic diseases and complex liver conditions, including alpha-1 antitrypsin deficiency (搜索), positioning itself in the specialty pharmaceutical and orphan drug markets where unmet medical needs remain substantial.
Market Context and Analyst Outlook
Over the last 12 months, the Arrowhead stock price has climbed 217.7%, compared with an 18.8% rise in the S&P 500 over the same period. Given this context and the amount of shares sold, the transaction appears routine, with Perry still directly holding 111,459 shares, signaling continued confidence in the company.
According to CNN, all 14 analysts who cover the stock rate it a buy. The median one-year price target is $109.50, representing a 26.8% gain from the current price of $86.34. The highest price target of $126 would represent a gain of nearly 46%, while the lowest price target of $100 would still represent a gain of 15.8%.